Neogen Chemicals Q2FY26: Fire, Lithium, and Financial Alchemy — The ₹348 Cr Blaze that Burned the Margins but Ignited the Curiosity
1. At a Glance
In a plot straight out of a corporate soap opera, Neogen Chemicals Ltd (NSE: NEOGEN) — the lithium-laced darling of India’s specialty chemicals space — reported Q2FY26 results that made analysts double-check their calculators and insurance companies double-check their clauses. The stock closed at ₹1,452, with a market cap of ₹3,831 crore and a P/E of 117. That’s right — it’s trading at a valuation hotter than its own Dahej plant, which recently suffered a ₹348 crore fire loss (yes, you read that correctly).
The company has already received ₹80.9 crore from its ₹334.6 crore insurance claim, but profits went up in smoke — Q2 PAT fell 69% YoY to ₹3.37 crore, even as sales grew 7.9% to ₹208.66 crore. The ROE stands at 5.59%, ROCE at 8.82%, and Debt/Equity ratio at 0.76 — because apparently, fire isn’t the only thing that’s leveraged.
Despite the chaos, Neogen continues to pour lithium — and cash — into capacity expansion, including its mega Dahej SEZ and the upcoming Pakhajan plant. From bromine chemistry to battery electrolytes, this is a company that’s been trying to turn the “specialty chemical” tag into “special narrative.”
So, what happens when a high-P/E, low-profit, capex-hungry chemical company faces a literal firestorm? Grab your safety goggles; we’re diving in.
2. Introduction
There are two kinds of chemical companies in India: those that quietly compound wealth, and those that set the market (and sometimes their plants) on fire. Neogen Chemicals proudly sits in the latter category.
Founded in 1991, Neogen is the lab rat that grew up in India’s specialty chemical ecosystem — a company that began with bromine-based intermediates and today wants to power your electric vehicles and your pharma drugs at the same time. From organolithium reagents to electrolyte salts, they’re not just selling molecules; they’re selling a futuristic dream — one lithium ion at a time.
But let’s face it — the dream is expensive. With a ₹1,500 crore capex pipeline, a fire worth ₹348 crore, and a P/E of 117, Neogen’s financials scream “science project meets venture capital experiment.” Their PAT of ₹26 crore (TTM) feels like a rounding error in their balance sheet, but their ambitions are global: 29+ export markets, 246 products, and even a Japanese JV (Morita) for lithium electrolyte salts.
Yet, the stock is down 31.5% over the past year, proving once again that chemistry can be volatile — not just in the lab, but also in the stock market.
So, the question is: can Neogen reinvent itself post-fire, or will it evaporate like an uncooled lithium cell?
3. Business Model – WTF Do They Even Do?
Let’s break it down before your eyes glaze over like a beaker of sodium bromide.
Neogen Chemicals makes bromine and lithium-based organic and inorganic compounds — these are used in everything from pharma APIs to battery electrolytes, agrochemicals, flavors & fragrances, and semiconductors. If it smells, shocks, or cures something — Neogen probably supplies an intermediate for it.
They’ve got two key divisions:
Organic Chemicals (84% of revenue): The bread and butter — bromine-based compounds and advanced intermediates for pharma and agri companies.
Inorganic Chemicals (16% of revenue): Mainly lithium-based chemicals for specialty and energy applications.
Then comes the fun part: Custom Synthesis and Contract Manufacturing. This means if Pfizer or Divi’s wants something weird synthesized, Neogen says, “Give us the formula; we’ll do the messy part.”
Their client list reads like the who’s who of Indian pharma — Aurobindo, Divis, Piramal, Sun Pharma, Hetero, and even Solvay. Basically, Neogen supplies the chemistry; the rest of the world supplies the revenue.
But the company isn’t stopping at molecules. With Neogen Ionics (a subsidiary) and Japanese tech from MU Iconic Solutions, they’re now building India’s first commercial lithium electrolyte plant. Because when everyone’s talking EVs, you don’t want to be the only guy still selling bromine.
4. Financials Overview
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue (₹ Cr)
208.66
193.36
186.73
7.9%
11.7%
EBITDA (₹ Cr)
29.96
34.51
31.51
-13.1%
-4.9%
PAT (₹ Cr)
3.37
10.96
10.26
-69.2%
-67.2%
EPS (₹)
1.28
4.15
3.89
-69.2%
-67.1%
Commentary: Revenue is up, profits are down — classic Neogen move. Margins slipped to 14.36% from the usual 17–18% range. Fire losses and insurance accounting ensured the bottom line looked like a chemistry experiment gone wrong. With an annualized EPS of ₹5.12, the P/E (117) looks like it was borrowed from the EV sector.
5. Valuation Discussion – Fair Value Range
Let’s bring out the calculators and sarcasm:
Method 1: P/E Based
Current EPS (TTM): ₹9.87
Industry PE (Specialty Chemicals): ~31.6
Fair Value Range = ₹9.87 × (30–40) = ₹296 – ₹395
Method 2: EV/EBITDA
EV: ₹4,423 Cr
EBITDA (TTM): ₹137 Cr
EV/EBITDA = 32.2x
Industry range ~15–25x → Fair EV range = ₹2,055 – ₹3,425 Cr → Equity Value ≈ ₹3,000 – ₹3,300 Cr → Fair Value = ₹1,150 – ₹1,250 per share.
🧾 Educational Disclaimer: This fair value range (₹1,150 – ₹1,400) is for educational purposes only and not a buy/sell call. Or as Neogen might put it — “handle with gloves and ventilation.”
